Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer

INTRODUCTION: Previous studies have shown interference between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing efficacy. In this randomised controlled trial we investigated whether intercalated erlotinib with chemotherapy was super...

Descripción completa

Detalles Bibliográficos
Autores principales: Gijtenbeek, Rolof G.P., van der Noort, Vincent, Aerts, Joachim G.J.V., Staal-van den Brekel, Jeske A., Smit, Egbert F., Krouwels, Frans H., Wilschut, Frank A., Hiltermann, T. Jeroen N., Timens, Wim, Schuuring, Ed, Janssen, Joost D.J., Goosens, Martijn, van den Berg, Paul M., de Langen, A. Joop, Stigt, Jos A., van den Borne, Ben E.E.M., Groen, Harry J.M., van Geffen, Wouter H., van der Wekken, Anthonie J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574558/
https://www.ncbi.nlm.nih.gov/pubmed/36267895
http://dx.doi.org/10.1183/23120541.00239-2022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574558/
https://www.ncbi.nlm.nih.gov/pubmed/36267895
http://dx.doi.org/10.1183/23120541.00239-2022

Ejemplares similares